Business Context and Reporting Period
This Form 6-K filing by Nokia Corporation is dated January 22, 2025. The report serves as a notification of managers' transactions pursuant to Article 19 of the EU Market Abuse Regulation. Nokia operates as a B2B technology innovation leader focusing on mobile, fixed, and cloud networks, as well as intellectual property and research through Nokia Bell Labs.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a regulatory disclosure of share-based incentive receipts by company managers and does not contain financial performance data.
Material Changes
No material changes to financial performance or business operations are reported in this filing. The document details the receipt of shares by various senior managers and closely associated persons on January 22, 2025, outside of a trading venue. These transactions are classified as "Receipt of a Share-Based Incentive."
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The "About Nokia" section reiterates the company's strategic focus on creating secure, reliable, and sustainable networks and digital services but offers no new forward-looking statements.
Important Facts for Investors
- Transaction Type: All reported transactions are non-market receipts of share-based incentives, not open market sales or purchases.
- Key Personnel Involved: Transactions were reported for CFO Marco Wirén (36,729 shares), Senior Manager Raghav Sahgal (89,000 shares), Senior Manager Nishant Batra (78,821 shares), and several other senior managers.
- Valuation Data: The unit price and volume-weighted average price are listed as "N/A" for all transactions, as they occurred outside a trading venue.
- Regulatory Compliance: The filing satisfies disclosure requirements under the EU Market Abuse Regulation for Persons Discharging Managerial Responsibilities (PDMRs).